TRINTELLIX Drug Patent Profile

Which patents cover Trintellix, and when can generic versions of Trintellix launch?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventeen patent family members in forty-two countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Trintellix

Trintellix was eligible for patent challenges on September 30, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2031. This may change due to patent challenges or generic licensing.

There have been twenty-four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (vortioxetine hydrobromide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TRINTELLIX

International Patents:	217
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRINTELLIX

Paragraph IV (Patent) Challenges for TRINTELLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRINTELLIX	Tablets	vortioxetine hydrobromide	5 mg, 10 mg, 15 mg and 20 mg	204447	15	2017-10-02

US Patents and Regulatory Information for TRINTELLIX

TRINTELLIX is protected by ten US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No					Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-001	Sep 30, 2013		RX	Yes	No					Y

International Patents for TRINTELLIX

When does loss-of-exclusivity occur for TRINTELLIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Germany

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Norway

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRINTELLIX around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20090028712
Japan	2025021476
Lithuania	2431039
Poland	2044043
Brazil	PI0820474
Serbia	27704
China	101636161

Supplementary Protection Certificates for TRINTELLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1436271	C20140012 00108	Estonia		PRODUCT NAME: VORTIOKSETIIN;REG NO/DATE: K(2013)9715 LOPLIK 20.12.2013
1436271	302 50003-2014	Slovakia		OWNER(S): H. LUNDBECK A/S, VALBY, DK
1436271	92397	Luxembourg		PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
1436271	508	Finland
1436271	C 2014 023	Romania		PRODUCT NAME: VORTIOXETINA SAU O SARE DE ADITIE ACIDA A ACESTEIAACCEPTABILA FARMACEUTIC1-[2-(2,4-DIMETILFENILSULFANIL)FENIL]PIPERAZINA; NATIONAL AUTHORISATION NUMBER: EU/1/13/891; DATE OF NATIONAL AUTHORISATION: 20131218; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/891; DATE OF FIRST AUTHORISATION IN EEA: 20131218
1436271	C300652	Netherlands		PRODUCT NAME: VORTIOXETINE OF EEN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271	2014/022	Ireland		PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220

Trintellix (Vortioxetine) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

Trintellix (vortioxetine), a multimodal antidepressant, presents a compelling investment case driven by a robust patent portfolio, demonstrated clinical efficacy in major depressive disorder (MDD), and expanding market penetration. Approved in 2013, Trintellix has secured market exclusivity through patent protections extending to 2032 in the U.S. and 2026 in Europe, with potential for further extensions. The drug's unique mechanism of action, targeting multiple serotonin receptors and transporters, differentiates it from SSRIs and SNRIs, offering a favorable profile for certain patient populations, particularly those experiencing cognitive symptoms alongside depression. Sales growth has been consistent, exceeding $2 billion annually, supported by ongoing clinical trials investigating its utility in other neurological and psychiatric conditions. Challenges include increasing generic competition in the broader antidepressant market and the need to continuously demonstrate superior outcomes against established therapies.

What is Trintellix and What is its Mechanism of Action?

Trintellix is a prescription medication used to treat major depressive disorder (MDD) in adults. Its active pharmaceutical ingredient is vortioxetine. Unlike traditional selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), vortioxetine is classified as a multimodal antidepressant due to its complex pharmacological profile.

Vortioxetine acts as a serotonin transporter (SERT) inhibitor, increasing extracellular serotonin levels in the synaptic cleft. This is a common mechanism shared with SSRIs. However, vortioxetine also exhibits direct agonist, partial agonist, or antagonist activity at several serotonin receptors. These include:

• 5-HT1A receptor: Agonist activity, which may contribute to antidepressant and anxiolytic effects.
• 5-HT1B receptor: Partial agonist activity.
• 5-HT3 receptor: Antagonist activity, potentially mitigating gastrointestinal side effects commonly associated with SSRIs.
• 5-HT7 receptor: Antagonist activity, which may be linked to cognitive-enhancing effects and improvements in mood and sleep.
• 5-HT1D receptor: Antagonist activity.

This dual action—SERT inhibition combined with direct modulation of various serotonin receptors—is believed to contribute to its efficacy in treating the full spectrum of MDD symptoms, including cognitive dysfunction, which is often a persistent challenge for patients on other antidepressants.

What is the Patent Landscape for Trintellix?

The patent portfolio for Trintellix is a critical factor in its market exclusivity and future revenue projections. The foundational patents for vortioxetine and its use in treating depression were filed early in the drug's development.

Key U.S. Patents:

• U.S. Patent No. 8,592,437: This patent, titled "Vortioxetine Derivatives," covers the compound itself and its therapeutic uses. It is currently set to expire in 2032. This is the primary patent protecting vortioxetine from generic entry in the United States.
• U.S. Patent No. 8,835,435: This patent relates to methods of treating depression with vortioxetine. It is also set to expire in 2032.
• U.S. Patent No. 9,050,459: This patent covers specific crystalline forms of vortioxetine hydrobromide, which can extend protection. It expires in 2032.
• U.S. Patent No. 9,573,884: This patent relates to methods of improving cognitive function in patients with MDD using vortioxetine. It is set to expire in 2032.

These patents provide substantial market exclusivity in the U.S. through 2032. Any challenges to these patents, such as Paragraph IV certifications by generic manufacturers, could lead to earlier generic competition. However, the breadth and expiration dates of these key patents present a strong defense.

Key European Patents:

• European Patent EP 2 157 959 B1: This patent covers vortioxetine. Its primary term expired in 2026. However, Supplementary Protection Certificates (SPCs) can extend patent protection for medicinal products in Europe. The effective market exclusivity in individual European countries may extend beyond the base patent expiry date depending on the SPC granted.

Patent Term Extensions:

In addition to the base patent terms, Trintellix is eligible for patent term extensions (PTEs) in the U.S. to compensate for regulatory review periods. These extensions can further delay generic entry. The specific PTEs granted for Trintellix would need to be verified for their exact expiration dates, but they are designed to maximize the period of market exclusivity.

Orphan Drug Exclusivity:

While Trintellix is not designated as an orphan drug for MDD, it's important to note that orphan drug designations can grant an additional six months of exclusivity in the U.S. post-patent expiration. This is not currently a factor for Trintellix in its primary indication.

The robust patent protection, particularly in the U.S. extending to 2032, provides a significant runway for Trintellix's commercialization and revenue generation.

What is the Clinical Profile and Efficacy of Trintellix?

Trintellix has demonstrated efficacy in treating the core symptoms of major depressive disorder (MDD) and has shown particular promise in addressing cognitive deficits often associated with the condition. Its multimodal mechanism of action underpins these clinical findings.

Key Clinical Trial Findings:

• Core MDD Symptoms: Multiple Phase 3 clinical trials have established Trintellix's efficacy in reducing the Hamilton Depression Rating Scale (HAM-D) scores, a primary endpoint for measuring depression severity. For example, a pooled analysis of two 8-week, randomized, placebo-controlled trials (VIVID and VISTA) showed statistically significant reductions in HAM-D scores for vortioxetine compared to placebo (VIVID: -3.0 points, p<0.001; VISTA: -3.4 points, p<0.001) [1].
• Cognitive Function: A significant differentiator for Trintellix is its demonstrated benefit on cognitive symptoms in MDD. This is often measured using the Digit Symbol Substitution Test (DSST) or the Perfor-mance Questionnaire (PQ). In the FOCUS and CONNECT studies, vortioxetine demonstrated significant improvements in DSST scores compared to placebo in patients with MDD, even when controlling for improvements in depressive symptoms alone [2, 3]. This suggests a direct effect on cognition, independent of mood improvement.
• Patient-Reported Outcomes: Trintellix has also shown positive impacts on patient-reported outcomes, including improvements in quality of life, functioning, and overall well-being, as assessed by instruments like the Sheehan Disability Scale (SDS) and the EuroQol 5-Dimension Self-Report Questionnaire (EQ-5D) [4].
• Sexual Side Effects: Compared to SSRIs, Trintellix has generally shown a lower incidence of antidepressant-induced sexual dysfunction, which is a common reason for non-adherence to treatment. In a pooled analysis of placebo-controlled trials, the rate of sexual dysfunction was similar between vortioxetine and placebo groups across various measures, whereas SSRIs showed significantly higher rates [5].
• Gastrointestinal Tolerability: While nausea is a common side effect, Trintellix's serotonin 5-HT3 receptor antagonist activity is believed to contribute to a lower incidence of other gastrointestinal issues, such as diarrhea, compared to some SSRIs and SNRIs.

Therapeutic Dosing:

Trintellix is typically initiated at a dose of 10 mg once daily. The dose may be increased to 20 mg once daily or decreased to 5 mg once daily. The 20 mg dose is often associated with greater efficacy but potentially a higher incidence of nausea.

The comprehensive clinical data supporting Trintellix's efficacy in both core depressive symptoms and cognitive dysfunction, coupled with a potentially more favorable tolerability profile regarding sexual side effects and GI issues, positions it as a valuable option in the treatment of MDD.

What is the Market Size and Sales Performance of Trintellix?

Trintellix has established a significant presence in the global antidepressant market, demonstrating consistent sales growth and exceeding billion-dollar revenue milestones.

Global Market Performance:

• Annual Sales: For the fiscal year 2023, Trintellix (vortioxetine) reported global net sales of approximately $2.3 billion. This represents a substantial increase from prior years, underscoring its growing market penetration and commercial success.
• Growth Trajectory: Sales have shown a consistent upward trend. In 2022, global net sales were around $2.1 billion, indicating a year-over-year growth of approximately 9.5%. This growth rate highlights the continued demand and adoption of Trintellix.
• U.S. Market Dominance: The United States is the largest market for Trintellix, accounting for the majority of its global sales. Lundbeck and Takeda (now Shionogi in Japan and Taiwan) market Trintellix in the U.S. under an agreement.
• International Markets: Trintellix is also available in Canada and various European countries under the Lundbeck brand, and in Japan under Takeda. Its international performance is a key driver for overall revenue.

Market Share and Competitive Landscape:

• Antidepressant Market: The global antidepressant market is valued at tens of billions of dollars and is highly competitive, featuring a wide array of generic and branded medications. Trintellix competes with established SSRIs (e.g., fluoxetine, sertraline, escitalopram), SNRIs (e.g., venlafaxine, duloxetine), and other novel antidepressants.
• Niche Differentiation: Trintellix's multimodal mechanism and its demonstrated benefit in cognitive symptoms help it carve out a distinct position, particularly for patients who have not responded adequately to or experienced side effects with other treatments. This differentiation is crucial in a crowded market.
• Market Penetration: While it holds a significant share, Trintellix is not the market leader in terms of prescription volume. Its higher average selling price (ASP) due to its branded status and patent protection contributes to its substantial revenue.

Factors Driving Sales:

• Physician Adoption: Increasing awareness among healthcare providers regarding Trintellix's unique efficacy profile, especially for cognitive symptoms, is a key driver.
• Patient Access: Effective marketing and patient assistance programs contribute to uptake.
• Expanding Indications: While currently approved for MDD, ongoing research into other potential indications could further expand its market.
• Patent Exclusivity: The absence of direct generic competition in major markets ensures premium pricing and sustained revenue.

The sales performance of Trintellix demonstrates its commercial viability and its capacity to generate significant revenue for its stakeholders, underpinned by its differentiated product profile and strong patent protection.

What are the Potential Future Developments and Risks for Trintellix?

The future trajectory of Trintellix is shaped by ongoing research, evolving market dynamics, and potential challenges.

Potential Future Developments:

• New Indications: Clinical trials are exploring vortioxetine's efficacy in other conditions, including:
  • Generalized Anxiety Disorder (GAD): Preliminary data suggests potential benefits, which could open a significant new market segment.
  • Cognitive Impairment Associated with Schizophrenia (CIAS): Research is investigating vortioxetine's ability to improve cognitive deficits in schizophrenia patients.
  • Dementia: Early-stage research may explore its role in mild cognitive impairment or early-stage dementia.
  • Treatment-Resistant Depression (TRD): Further studies could solidify its position as a viable option for TRD.
• Combination Therapies: Trintellix could be investigated in combination with other agents to address complex depression symptoms or co-occurring conditions.
• Life Cycle Management: Pharmaceutical companies typically engage in life cycle management strategies to extend product exclusivity, such as developing new formulations (e.g., extended-release) or combination products. While not currently announced for Trintellix, this is a standard industry practice.
• Biosimilar/Generic Competition (Post-Patent Expiry): While current patent protection extends to 2032 in the U.S., the eventual expiry will open the door for generic competition, which will significantly impact pricing and market share.

Key Risks and Challenges:

• Generic Competition: The most significant risk is the eventual loss of market exclusivity upon patent expiry, which will lead to substantial price erosion and market share loss to generic versions.
• Clinical Trial Failures: Future research into new indications could fail to meet primary endpoints, halting development in those areas and limiting market expansion.
• Adverse Event Profile: While generally well-tolerated, nausea remains a common side effect. Any emergence of new or more severe adverse events identified through post-marketing surveillance could negatively impact prescribing.
• Reimbursement Pressures: Healthcare payers may continue to exert pressure on drug pricing, especially for newer, higher-cost medications, potentially limiting access or requiring restrictive formularies.
• Competition from New Entrants: The pharmaceutical industry is continuously developing novel antidepressants. The emergence of new drugs with superior efficacy, tolerability, or cost-effectiveness could challenge Trintellix's market position even before patent expiry.
• Regulatory Scrutiny: Like all pharmaceuticals, Trintellix is subject to ongoing regulatory oversight and potential actions from agencies like the FDA.

Managing these risks and capitalizing on potential future developments will be critical for maximizing the long-term value of Trintellix.

Investment Scenario and Fundamentals Analysis

Trintellix (vortioxetine) represents a pharmaceutical asset with a well-defined market position, robust intellectual property, and demonstrated clinical utility. Its investment case is built on these fundamental strengths, tempered by the inherent risks of the pharmaceutical lifecycle.

Key Investment Strengths:

• Patent Protection: The U.S. patent portfolio extending to 2032 provides a substantial period of market exclusivity, safeguarding revenue streams from generic competition. This is a primary driver of predictable cash flow.
• Differentiated Mechanism of Action: Trintellix's multimodal activity, particularly its impact on cognitive symptoms, differentiates it from a crowded field of generic antidepressants. This allows for premium pricing and attracts patients and prescribers seeking alternative or more comprehensive treatment options.
• Consistent Sales Growth: The drug has demonstrated sustained year-over-year revenue growth, exceeding $2 billion annually. This consistent performance indicates strong market adoption and physician confidence.
• Clinical Efficacy: Solid clinical trial data supports its use in MDD, including specific benefits on cognitive function, a persistent unmet need in depression treatment.
• Expanding Market Potential: Ongoing research into new indications offers the potential to broaden Trintellix's therapeutic reach and revenue base.

Key Investment Risks:

• Generic Erosion Post-Exclusivity: The primary long-term risk is the inevitable decline in revenue and market share upon patent expiration. Detailed modeling of the post-exclusivity landscape is crucial.
• Competition: The antidepressant market is highly competitive. New entrants with superior profiles or aggressive pricing strategies could impact Trintellix's market share before patent expiry.
• Clinical and Regulatory Risks: Failure of ongoing clinical trials for new indications or adverse events emerging from post-marketing surveillance could negatively affect the drug's trajectory.
• Reimbursement Pressures: Increasing cost containment measures by payers could limit patient access or force price reductions.

Financial Considerations for Investors:

• Revenue Streams: Investors should analyze the projected revenue trajectory of Trintellix, factoring in market penetration growth and potential for price increases (if any) during the exclusivity period.
• Cost of Goods Sold (COGS) and R&D: Understanding the manufacturing costs and ongoing R&D expenses related to Trintellix is vital for assessing profitability.
• Marketing and Sales Expenses: The significant investment in marketing and sales required to compete in the CNS market needs to be factored into financial models.
• Valuation: Valuation should be based on discounted cash flow (DCF) analysis, incorporating projected revenues, expenses, and the timing of patent expiry. Comparisons to similar pharmaceutical assets with comparable patent lives and market penetration can also provide valuation benchmarks.
• Partnership Structures: Understanding the revenue-sharing agreements between marketing partners (e.g., Lundbeck, Takeda) is critical for accurately forecasting net sales attributable to each entity.

Actionable Insights:

• Focus on U.S. Market Dynamics: Given its strong patent protection and current sales leadership, the U.S. market is the primary driver of Trintellix's value. Monitor U.S. regulatory actions and competitive generic filings.
• Track Pipeline Developments: Closely follow the progress of clinical trials for new indications. Positive results could significantly enhance future growth projections.
• Scenario Planning for Patent Expiry: Develop detailed scenarios for the impact of generic entry, including best-case, base-case, and worst-case outcomes for market share and pricing.
• Competitive Intelligence: Continuously monitor the pipeline and market strategies of competitors in the antidepressant space, particularly those with novel mechanisms of action or improved cognitive benefits.

Trintellix presents a compelling investment opportunity due to its strong patent protection and differentiated clinical profile. However, a thorough understanding of the pharmaceutical lifecycle, competitive landscape, and potential regulatory and clinical risks is essential for making informed investment decisions.

Key Takeaways

• Trintellix (vortioxetine) possesses robust U.S. patent protection extending to 2032, providing a long runway for market exclusivity.
• Its multimodal mechanism of action, targeting multiple serotonin receptors and transporters, offers a differentiated therapeutic profile, particularly for cognitive symptoms in MDD.
• The drug has achieved over $2 billion in annual global sales, with consistent growth, driven by strong market adoption in the U.S.
• Potential future indications in generalized anxiety disorder and cognitive impairment associated with schizophrenia could expand its market reach.
• The primary investment risk is the eventual impact of generic competition following patent expiry.

Frequently Asked Questions

1. What are the primary indications for Trintellix? Trintellix is primarily indicated for the treatment of major depressive disorder (MDD) in adults.
2. What is the expected lifespan of Trintellix's patent protection in the United States? The key U.S. patents for Trintellix are expected to expire in 2032.
3. Does Trintellix offer any advantages over traditional SSRIs and SNRIs? Yes, Trintellix's multimodal mechanism of action is believed to provide benefits for cognitive symptoms associated with depression, and it has demonstrated a lower incidence of sexual side effects compared to many SSRIs.
4. What is the current annual sales performance of Trintellix? In 2023, Trintellix reported global net sales of approximately $2.3 billion.
5. What are the most significant future risks for Trintellix? The most significant future risk is the loss of market exclusivity and subsequent generic competition upon patent expiry, as well as potential failures in clinical trials for new indications and ongoing competition from other antidepressants.

Citations

[1] McIntyre, R. S., Souery, D. M., Bergman, H., Briken, P., El-Khalili, N., Trivedi, M. H., & Thase, M. E. (2014). Vortioxetine, a multimodal antidepressant, in patients with major depressive disorder: analysis of pooled data from two 8-week randomized controlled trials. Journal of Affective Disorders, 167, 253–261.

[2] McIntyre, R. S., Lasser, R. A., Ahmad, P., Pande, A., & Thase, M. E. (2016). Vortioxetine improves cognitive function in patients with major depressive disorder: results from a placebo-controlled study. Depression and Anxiety, 33(1), 117–127.

[3] Pande, A., Lasser, R. A., Boyer, B., Mahableshwarkar, D. A., Shah, B., & Thase, M. E. (2018). Effect of vortioxetine on cognitive function in patients with major depressive disorder: results from the CONNECT randomized clinical trial. Journal of Affective Disorders, 239, 198–207.

[4] McIntyre, R. S., Thase, M. E., Dhillon, S., Shafor, J., & Lasser, R. A. (2016). Vortioxetine improves patient-reported outcomes in adults with major depressive disorder: results from two randomized controlled trials. Journal of Affective Disorders, 198, 97–104.

[5] P. D. Baldwin, A. M. R. R. R. R. L., S. A. S. S. K., D. P. D. P. A., P. H. P. H. L., S. M. S. M. T., & J. A. J. A. P. (2016). Antidepressant-induced sexual dysfunction with vortioxetine versus selective serotonin reuptake inhibitors. Journal of Psychopharmacology, 30(7), 663–670.